Product Description
Ferric citrate (FC) is an iron-containing phosphate binder that has been shown to effectively decrease serum phosphate, increase hemoglobin, and replete iron stores in patients with chronic kidney disease. Intestinal absorption of iron from FC results in increases in serum iron, ferritin, and transferrin saturation, effects that occur over 12 to 24 weeks and subsequently appear to plateau. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/27236135/)
Mechanisms of Action: TFR Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Bangladesh | Belgium | Brazil | European Medicines Agency | Hungary | Ireland | Italy | Japan | Latvia | Lithuania | Pakistan | Poland | Portugal | Sweden | Switzerland | Taiwan | Turkey | United States
Approved Indications: None
Known Adverse Events: None
Company: Akebia
Company Location: CAMBRIDGE MA 02142
Company CEO: John P. Butler
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 3
Highest Development Phases
Phase 3: Anemia, Iron-Deficiency|Deficiency Diseases|Hyperphosphatemia|Kidney Failure, Chronic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| KRX-0502-309 | P3 |
Not yet recruiting |
Kidney Failure, Chronic|Deficiency Diseases|Anemia, Iron-Deficiency |
2027-01-01 |
14% |
| KRX-0502-308 | P3 |
Recruiting |
Kidney Failure, Chronic|Hyperphosphatemia |
2025-12-01 |
17% |
| FRONTIER | P3 |
Completed |
Kidney Failure, Chronic|Hyperphosphatemia|Anemia, Iron-Deficiency |
2024-01-24 |
14% |